PL408169A1 - Zastosowanie porfiryn kobaltu - Google Patents
Zastosowanie porfiryn kobaltuInfo
- Publication number
- PL408169A1 PL408169A1 PL408169A PL40816914A PL408169A1 PL 408169 A1 PL408169 A1 PL 408169A1 PL 408169 A PL408169 A PL 408169A PL 40816914 A PL40816914 A PL 40816914A PL 408169 A1 PL408169 A1 PL 408169A1
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- peripheral blood
- application
- neutropenia
- agent
- Prior art date
Links
- NVJHHSJKESILSZ-UHFFFAOYSA-N [Co].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical class [Co].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 NVJHHSJKESILSZ-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000005259 peripheral blood Anatomy 0.000 abstract 2
- 239000011886 peripheral blood Substances 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- 208000025212 Constitutional neutropenia Diseases 0.000 abstract 1
- 206010052210 Infantile genetic agranulocytosis Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 230000000735 allogeneic effect Effects 0.000 abstract 1
- 238000002617 apheresis Methods 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Przedmiotem wynalazku jest zastosowanie porfiryny kobaltu do wytwarzania środka do mobilizacji komórek ze szpiku kostnego do krwi obwodowej, korzystnie środka stosowanego w leczeniu neutropenii wrodzonych, w leczeniu oraz profilaktyce neutropenii spowodowanych chemioterapią, radioterapią oraz indukowanych farmakologicznie, w leczeniu ostrej białaczki szpikowej, ostrej białaczki limfocytarnej, zespołów mielodysplastycznych oraz w celu zwiększania ilości krążących we krwi obwodowej hematopoetycznych komórek macierzystych, w celu późniejszej ich izolacji w procesie aferezy i przeszczepiania allogenicznego lub autologicznego.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL40816914A PL233504B1 (pl) | 2014-05-09 | 2014-05-09 | Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek |
| EP15727081.0A EP3139917B1 (en) | 2014-05-09 | 2015-05-09 | Cobalt protorphyrin ix for the treatment of blood-related disorders |
| PCT/PL2015/050014 WO2015171001A1 (en) | 2014-05-09 | 2015-05-09 | Cobalt porphyrins for the treatment of blood-related disorders |
| US15/309,485 US10010557B2 (en) | 2014-05-09 | 2015-05-09 | Cobalt porphyrins for the treatment of blood-related disorders |
| US16/018,229 US10328085B2 (en) | 2014-05-09 | 2018-06-26 | Cobalt porphyrins for the treatment of blood-related disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL40816914A PL233504B1 (pl) | 2014-05-09 | 2014-05-09 | Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL408169A1 true PL408169A1 (pl) | 2015-11-23 |
| PL233504B1 PL233504B1 (pl) | 2019-10-31 |
Family
ID=53284481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL40816914A PL233504B1 (pl) | 2014-05-09 | 2014-05-09 | Protoporfiryna IX kobaltu do stosowania w leczeniu neutropenii i białaczek |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10010557B2 (pl) |
| EP (1) | EP3139917B1 (pl) |
| PL (1) | PL233504B1 (pl) |
| WO (1) | WO2015171001A1 (pl) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63501219A (ja) * | 1986-02-21 | 1988-05-12 | ザ ロツクフエラ− ユニバ−シテイ | 内分泌系ホルモン生成抑制用非経口投与治療組成物および方法 |
| US5192757A (en) | 1990-12-20 | 1993-03-09 | Glaxo Inc. | Cobalt porphyrins |
| US5149697A (en) | 1991-04-18 | 1992-09-22 | Glaxo Inc. | Cobalt porphyrin pharmaceutical compositions |
| US5776966A (en) | 1992-05-27 | 1998-07-07 | University Of British Columbia | Selective cell inactivation in blood |
| WO2005084665A1 (ja) | 2004-03-04 | 2005-09-15 | Makoto Yuasa | 金属ポルフィリン錯体包埋ニオソーム、その製造法およびこれを利用する医薬 |
| JPWO2011099602A1 (ja) * | 2010-02-12 | 2013-06-17 | 学校法人日本大学 | ポルフィリン誘導体および放射線力学療法におけるその使用 |
-
2014
- 2014-05-09 PL PL40816914A patent/PL233504B1/pl unknown
-
2015
- 2015-05-09 EP EP15727081.0A patent/EP3139917B1/en active Active
- 2015-05-09 WO PCT/PL2015/050014 patent/WO2015171001A1/en not_active Ceased
- 2015-05-09 US US15/309,485 patent/US10010557B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170196882A1 (en) | 2017-07-13 |
| EP3139917B1 (en) | 2019-07-03 |
| WO2015171001A1 (en) | 2015-11-12 |
| US10010557B2 (en) | 2018-07-03 |
| PL233504B1 (pl) | 2019-10-31 |
| EP3139917A1 (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550216A1 (en) | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors | |
| MX389683B (es) | Composiciones terapeuticas, combinaciones y metodos de uso | |
| EA201992155A1 (ru) | Способы криогенного хранения | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| MX390537B (es) | Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm | |
| EA201790248A1 (ru) | Композиции носитель-антитело и способы их получения и применения | |
| PE20160167A1 (es) | Composiciones y metodos para alterar la senalizacion del segundo mensajero | |
| CL2016001055A1 (es) | Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras. | |
| CY1120201T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι με χρηση ανταγωνιστων σελεκτινης ε για κινητοποιηση αιμοποιητικων κυτταρων | |
| CL2016000150A1 (es) | Compuestos y composiciones como inhibidores de la mek | |
| CL2015002640A1 (es) | Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes | |
| MX373280B (es) | Anticuerpos anti-egfrviii y usos de los mismos. | |
| CR20160501A (es) | Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa | |
| MX393494B (es) | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). | |
| ECSP14000357A (es) | Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes | |
| CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| EA201592203A1 (ru) | Способы лечения таупатии | |
| CL2015002620A1 (es) | Derivados piridin-4-ilo | |
| MX2018009408A (es) | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. | |
| MX381544B (es) | Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. | |
| PH12019501108A1 (en) | Anti-gitr anti-binding protein and methods of use thereof |